Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Insight Molecular Diagnostics (IMDX) Shares Issued (2016 - 2026)

Insight Molecular Diagnostics' Shares Issued history spans 5 years, with the latest figure at $29.1 million for Q1 2025.

On a quarterly basis, Shares Issued changed N/A to $29.1 million in Q1 2025 year-over-year; TTM through Dec 2025 was $29.1 million, a 12.04% increase, with the full-year FY2025 number at $29.1 million, up 12.04% from a year prior.
Shares Issued hit $29.1 million in Q1 2025 for Insight Molecular Diagnostics, up from $10.2 million in the prior quarter.
Over the last five years, Shares Issued for IMDX hit a ceiling of $29.1 million in Q1 2025 and a floor of -$47000.0 in Q4 2021.
Historically, Shares Issued has averaged $7.0 million across 4 years, with a median of $1.8 million in 2021.
Biggest five-year swings in Shares Issued: plummeted 100.26% in 2021 and later skyrocketed 23709.52% in 2022.
Tracing IMDX's Shares Issued over 4 years: stood at -$47000.0 in 2021, then skyrocketed by 10738.3% to $5.0 million in 2022, then surged by 104.1% to $10.2 million in 2024, then surged by 185.58% to $29.1 million in 2025.
Business Quant data shows Shares Issued for IMDX at $29.1 million in Q1 2025, $10.2 million in Q4 2024, and $15.8 million in Q2 2024.